Get the Stockscreener App
71.88
2.67%
1.8594
Apogee Therapeutics Inc stock is traded at $71.88, with a volume of 278.33K.
It is up +2.67% in the last 24 hours and down -7.02% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$70.02
Open:
$70.1
24h Volume:
278.33K
Relative Volume:
0.32
Market Cap:
$4.92B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-26.10
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
-12.37%
1M Performance:
-7.02%
6M Performance:
+76.11%
1Y Performance:
+78.74%
1-Day Range:
$69.67
$72.36
1-Week Range:
$67.97
$82.00
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
72.04 | 4.78B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.36 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.58 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.73 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.94 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.99 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
(APGE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aug Shorts: What are TrueBlue Incs growth leversGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Aug Breakouts: Whats the RSI of Adicet Bio Inc stockPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com - Investing.com Nigeria
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns - Investing.com India
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk - marketscreener.com
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Bear Alert: Whats the beta of Apogee Therapeutics Inc stock2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
What are Apogee Therapeutics Incs growth leversJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Apogee's Pipeline Momentum Driving Investor Confidence? - RTTNews
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's Why - MarketBeat
Apogee Therapeutics stock hits all-time high at 81.0 USD - Investing.com
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling a 32.83% Potential Upside Amidst Promising Biotech Innovations - DirectorsTalk Interviews
Published on: 2026-01-13 09:29:07 - Улправда
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance
SG Americas Securities LLC Invests $5.33 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Positive Asthma Data and I&I Pipeline Plans Could Be A Game Changer For Apogee Therapeutics (APGE) - Yahoo Finance
A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Update And 2026 Pipeline Milestones - Sahm
Apogee Therapeutics (NASDAQ:APGE) Insider Sells $1,455,608.00 in Stock - MarketBeat
Apogee Therapeutics CMO sells $1.45 million in shares By Investing.com - Investing.com Canada
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView — Track All Markets
Apogee Therapeutics price target raised to $133 from $95 at Stifel - MSN
UBS Group Upgrades Apogee Therapeutics (NASDAQ:APGE) to Strong-Buy - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
What technical signals suggest for Apogee Therapeutics Inc. stockTrade Exit Report & Weekly Hot Stock Watchlists - ulpravda.ru
Can Apogee Therapeutics Inc. stock weather global recessionJuly 2025 Summary & Verified Technical Trade Signals - Улправда
Levels Update: How Apogee Therapeutics Inc. stock reacts to job market data2025 Market Trends & Fast Gaining Stock Strategy Reports - Улправда
Apogee Therapeutics (APGE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
What insider trading reveals about Apogee Therapeutics Inc. stock2025 Winners & Losers & Verified Momentum Stock Alerts - ulpravda.ru
Craig-Hallum Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $116 - 富途牛牛
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com South Africa
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation - Nasdaq
Will Apogee Therapeutics Inc. stock gain from lower inflationMarket Profile Overview & High Yield Portfolio Picks - Улправда
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data - Investing.com Nigeria
March 20th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):